beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team: a community of fearless innovators rigorous and honest in our research listening with open minds committed to each other
Company profile
Ticker
BEAM
Exchange
Website
CEO
John M. Evans
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Beam Therapeutics Securities Corporation • Guide Therapeutics, LLC ...
BEAM stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
27 Feb 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
27 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
14 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
8 Nov 23
8-K
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
31 Oct 23
8-K
Cost Associated with Exit or Disposal Activities
19 Oct 23
Latest ownership filings
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Amy Simon
3 Apr 24
4
Christine Bellon
3 Apr 24
4
Terry-Ann Burrell
3 Apr 24
4
John M. Evans
3 Apr 24
4
Giuseppe Ciaramella
3 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 177.73 mm | 177.73 mm | 177.73 mm | 177.73 mm | 177.73 mm | 177.73 mm |
Cash burn (monthly) | 21.08 mm | (no burn) | 36.09 mm | 33.19 mm | 29.93 mm | 29.45 mm |
Cash used (since last report) | 140.52 mm | n/a | 240.58 mm | 221.28 mm | 199.51 mm | 196.36 mm |
Cash remaining | 37.21 mm | n/a | -62.85 mm | -43.55 mm | -21.78 mm | -18.63 mm |
Runway (months of cash) | 1.8 | n/a | -1.7 | -1.3 | -0.7 | -0.6 |
Institutional ownership, Q3 2023
94.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 191 |
Opened positions | 34 |
Closed positions | 33 |
Increased positions | 78 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 1.60 tn |
Total shares | 76.88 mm |
Total puts | 376.70 k |
Total calls | 332.90 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 8.78 mm | $211.25 bn |
Vanguard | 6.81 mm | $163.90 bn |
BLK Blackrock | 6.52 mm | $156.87 bn |
FMR | 6.50 mm | $156.27 bn |
ARCH Venture Fund IX | 5.84 mm | $0.00 |
Farallon Capital Management | 4.48 mm | $107.79 bn |
Temasek | 4.32 mm | $103.84 bn |
STT State Street | 4.14 mm | $99.62 bn |
Farallon Capital Partners | 3.95 mm | $98.86 mm |
MWG Management | 2.35 mm | $56.44 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Giuseppe Ciaramella | Stock Option Common Stock | Grant | Acquire A | No | No | 4.22 | 12,979 | 54.77 k | 12,979 |
3 Apr 24 | Giuseppe Ciaramella | Stock Option Common Stock | Grant | Acquire A | No | No | 0.67 | 27,318 | 18.30 k | 27,318 |
3 Apr 24 | John M. Evans | Stock Option Common Stock | Grant | Acquire A | No | No | 4.22 | 53,965 | 227.73 k | 53,965 |
3 Apr 24 | John M. Evans | Stock Option Common Stock | Grant | Acquire A | No | No | 0.67 | 99,336 | 66.56 k | 99,336 |
2 Apr 24 | Amy Simon | Common Stock | Sell | Dispose S | No | Yes | 30.5415 | 16,530 | 504.85 k | 70,060 |
1 Apr 24 | Giuseppe Ciaramella | Common Stock | Sell | Dispose S | No | Yes | 32.12 | 4,534 | 145.63 k | 169,616 |
1 Apr 24 | John M. Evans | Common Stock | Sell | Dispose S | No | Yes | 32.13 | 18,102 | 581.62 k | 1,058,343 |
1 Apr 24 | Terry-Ann Burrell | Common Stock | Sell | Dispose S | No | Yes | 32.12 | 5,446 | 174.93 k | 70,137 |
1 Apr 24 | Christine Bellon | Common Stock | Sell | Dispose S | No | Yes | 32.12 | 3,401 | 109.24 k | 104,594 |
1 Apr 24 | Amy Simon | Common Stock | Sell | Dispose S | No | Yes | 32.13 | 7,157 | 229.95 k | 86,590 |
News
Bitcoin Surpasses $66,000; Core Emerges As Top Gainer
15 Apr 24
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
12 Apr 24
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
2 Apr 24
Bitcoin Trades Above $70,000 Following GDP, Jobless Claims Data; GateToken Emerges As Top Gainer
28 Mar 24
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
27 Mar 24
Press releases
2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers
22 Mar 24
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
28 Feb 24
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
27 Feb 24
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
5 Feb 24